Stempoint Capital L.P. is an investment fund managing more than $340 billion ran by Sean Tan. There are currently 42 companies in Mr. Tan’s portfolio. The largest investments include Syndax Pharmaceuticals Inc and Roivant Sciences Ltd, together worth $57.7 billion.
As of 6th August 2024, Stempoint Capital L.P.’s top holding is 1,412,176 shares of Syndax Pharmaceuticals Inc currently worth over $29 billion and making up 8.5% of the portfolio value.
Relative to the number of outstanding shares of Syndax Pharmaceuticals Inc, Stempoint Capital L.P. owns more than approximately 0.1% of the company.
In addition, the fund holds 2,712,741 shares of Roivant Sciences Ltd worth $28.7 billion.
The third-largest holding is Immunovant Inc worth $26.7 billion and the next is Crinetics Pharmaceuticals In worth $24.7 billion, with 551,095 shares owned.
Currently, Stempoint Capital L.P.'s portfolio is worth at least $340 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Stempoint Capital L.P. office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Sean Tan serves as the CCO, COO & Managing Partner at Stempoint Capital L.P..
In the most recent 13F filing, Stempoint Capital L.P. revealed that it had opened a new position in
Immunocore Hldgs Plc and bought 339,351 shares worth $11.5 billion.
The investment fund also strengthened its position in Syndax Pharmaceuticals Inc by buying
311,188 additional shares.
This makes their stake in Syndax Pharmaceuticals Inc total 1,412,176 shares worth $29 billion.
Syndax Pharmaceuticals Inc dropped approximately 0.1% in the past year.
On the other hand, there are companies that Stempoint Capital L.P. is getting rid of from its portfolio.
Stempoint Capital L.P. closed its position in Eli Lilly & Co on 13th August 2024.
It sold the previously owned 15,067 shares for $11.7 billion.
Sean Tan also disclosed a decreased stake in Roivant Sciences Ltd by 0.2%.
This leaves the value of the investment at $28.7 billion and 2,712,741 shares.
The two most similar investment funds to Stempoint Capital L.P. are Fairfield Advisors, Ltd and Marcho Partners LL.P.. They manage $340 billion and $340 billion respectively.
Stempoint Capital L.P.’s portfolio is diversified across 3 sectors.
Currently, their heaviest sector is Health Care — making up 61.6% of
the total portfolio value.
The fund focuses on investments in the United States as
47.6% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
14% of the total holdings value.
On the other hand, large-cap stocks make up only 4.8% of the portfolio.
The average market cap of the portfolio companies is close to $15.4 billion.
These positions were updated on August 13th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Syndax Pharmaceuticals Inc |
28.26%
1,412,176
|
$28,991,973,000 | 8.53% |
| Roivant Sciences Ltd |
23.67%
2,712,741
|
$28,673,672,000 | 8.44% |
| Immunovant Inc |
61.33%
1,011,879
|
$26,713,606,000 | 7.86% |
| Crinetics Pharmaceuticals In |
11.08%
551,095
|
$24,683,545,000 | 7.26% |
| Merus N.V |
23.43%
288,668
|
$17,080,486,000 | 5.02% |
| Arcellx Inc |
100.12%
280,709
|
$15,492,330,000 | 4.56% |
| Amicus Therapeutics Inc |
3.37%
1,495,047
|
$14,830,866,000 | 4.36% |
| Eli Lilly & Co |
Closed
15,067
|
$11,721,523,000 | |
| Immunocore Hldgs Plc |
Opened
339,351
|
$11,500,605,000 | 3.38% |
| Applied Therapeutics, Inc. |
9.63%
2,211,320
|
$10,326,864,000 | 3.04% |
| Merck & Co Inc |
Opened
81,508
|
$10,153,452,000 | 2.99% |
| GSK Plc |
Opened
245,933
|
$9,468,421,000 | 2.79% |
| Autolus Therapeutics plc |
10.22%
2,662,732
|
$9,266,307,000 | 2.73% |
| Arcutis Biotherapeutics Inc |
56.24%
965,392
|
$8,978,146,000 | 2.64% |
| Cabaletta Bio Inc |
17.35%
1,178,105
|
$8,812,225,000 | 2.59% |
| KalVista Pharmaceuticals Inc |
36.54%
736,765
|
$8,679,092,000 | 2.55% |
| Biohaven Ltd |
179.48%
233,255
|
$8,096,281,000 | 2.38% |
| Tarsus Pharmaceuticals, Inc. |
Closed
222,253
|
$8,078,897,000 | |
| Tourmaline Bio Inc |
Closed
274,219
|
$6,279,615,000 | |
| AnaptysBio Inc |
Closed
269,548
|
$6,070,221,000 | |
| Vistagen Therapeutics Inc. |
No change
1,848,582
|
$5,848,164,000 | 1.72% |
| Immatics N.v |
2.09%
502,207
|
$5,835,645,000 | 1.72% |
| Denali Therapeutics Inc |
Opened
251,010
|
$5,828,452,000 | 1.71% |
| Insmed Inc |
68.07%
86,980
|
$5,827,660,000 | 1.71% |
| Celldex Therapeutics Inc. |
Opened
144,467
|
$5,346,724,000 | 1.57% |
| Larimar Therapeutics, Inc. |
4.93%
704,349
|
$5,106,530,000 | 1.50% |
| Soleno Therapeutics Inc |
Closed
115,833
|
$4,957,652,000 | |
| Tscan Therapeutics Inc |
Opened
845,069
|
$4,943,654,000 | 1.45% |
| Edgewise Therapeutics Inc |
Opened
271,057
|
$4,881,737,000 | 1.44% |
| Acelyrin Inc |
Closed
714,773
|
$4,824,718,000 | |
| Corbus Pharmaceuticals Hldgs |
Opened
101,479
|
$4,591,925,000 | 1.35% |
| Moonlake Immunotherapeutics |
Closed
90,647
|
$4,553,199,000 | |
| Annexon Inc |
Closed
605,117
|
$4,338,689,000 | |
| Fulcrum Therapeutics Inc |
71.08%
696,464
|
$4,318,077,000 | 1.27% |
| Nurix Therapeutics, Inc. |
Opened
203,273
|
$4,242,308,000 | 1.25% |
| Pyxis Oncology Inc |
32.97%
1,202,675
|
$3,980,854,000 | 1.17% |
| Janux Therapeutics Inc |
23.59%
92,949
|
$3,893,634,000 | 1.15% |
| Avadel Pharmaceuticals plc |
Closed
223,660
|
$3,777,617,000 | |
| Disc Medicine Inc |
Closed
60,129
|
$3,743,632,000 | |
| IDEAYA Biosciences, Inc. |
16.47%
101,787
|
$3,573,742,000 | 1.05% |
| Spyre Therapeutics Inc |
141.68%
150,450
|
$3,537,080,000 | 1.04% |
| Perspective Therapeutics Inc |
Opened
343,810
|
$3,427,786,000 | 1.01% |
| Jasper Therapeutics Inc |
11.27%
143,775
|
$3,263,693,000 | 0.96% |
| Black Diamond Therapeutics I |
Opened
674,198
|
$3,141,763,000 | 0.92% |
| Taysha Gene Therapies, Inc. |
Closed
1,087,785
|
$3,121,943,000 | |
| Vigil Neuroscience Inc |
Opened
744,412
|
$2,977,648,000 | 0.88% |
| Neurogene Inc |
Opened
78,601
|
$2,860,290,000 | 0.84% |
| Astria Therapeutics Inc |
Closed
230,273
|
$2,676,878,000 | |
| Silence Therapeutics plc |
Opened
124,866
|
$2,372,454,000 | 0.70% |
| Protara Therapeutics Inc |
484.24%
984,113
|
$2,046,955,000 | 0.60% |
| Helix Acquisition Corp Ii |
No change
200,000
|
$2,044,000,000 | 0.60% |
| Effector Therapeutics Inc |
Closed
132,793
|
$1,910,891,000 | |
| Newamsterdam Pharma Company |
Closed
80,334
|
$1,899,899,000 | |
| Cg Oncology Inc |
Closed
40,723
|
$1,787,740,000 | |
| Achilles Therapeutics Plc |
Closed
1,385,750
|
$1,732,188,000 | |
| Surrozen Inc |
Opened
143,510
|
$1,571,435,000 | 0.46% |
| Perceptive Cap Solutions Cor |
Opened
150,000
|
$1,509,000,000 | 0.44% |
| Dianthus Therapeutics Inc |
Closed
43,456
|
$1,303,680,000 | |
| Praxis Precision Medicines I |
8.80%
29,259
|
$1,210,152,000 | 0.36% |
| Cargo Therapeutics Inc |
Closed
51,126
|
$1,141,132,000 | |
| Kyverna Therapeutics Inc |
Closed
41,000
|
$1,018,440,000 | |
| No transactions found | |||
| Showing first 500 out of 61 holdings | |||